Stock Report

All about this stock under one free report Last Updated: 07-Sep-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Avience Biomedicals Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: AVIENCE

₹275.00

up-down-arrow ₹4.50 (1.66%)

As on 04-Sep-2026 15:32IST

Market cap

info icon

₹151 Cr

Revenue (TTM)

info icon

₹45 Cr

P/E Ratio

info icon

17.2

P/B Ratio

info icon

2.8

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- 77.73 41.73 --
EBIT -- -- 154.04 83.48 --
Net Profit -- -- 158.85 92.64 --
EPS -- -- 110.89 67.39 --
Book Value -- -- 176.22 68.92 --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsMar-25Mar-24Mar-23
EBIT-Margin info 17.36--23.4114.55--
Net Margin info 11.93--15.738.78--
Return on equity info 32.82--49.9034.47--
Return on Capital info 27.53--34.1618.25--
Return on Assets info 11.58--15.906.20--
Debt to Equity (x) info ----0.972.44--

Profitability

View Detailed Peer Comparison

ROCE

34.16

Higher than Peers by 20.93

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
34.16
18.25
--
--
--
Peer Median
13.23
16.51
17.42
27.03
--
ROE

49.90

Higher than Peers by 35.87

Profit after tax / Average Net worth * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
49.90
34.47
--
--
--
Peer Median
14.03
12.58
14.29
18.94
--
ROA

15.90

Higher than Peers by 9.85

Profit after tax / Average Total assets * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
15.90
6.20
--
--
--
Peer Median
6.05
6.27
11.08
12.83
--
EBIT Margin

23.41

Higher than Peers by 11.49

Operating profit (EBIT) / Net Sales * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
23.41
14.55
--
--
--
Peer Median
11.92
17.72
10.64
19.57
--
Net Margin

15.73

Higher than Peers by 9.43

Net profit / Total Income (Net sales plus other income) * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
15.73
8.78
--
--
--
Peer Median
6.31
8.62
8.68
11.63
--
Cash Profit Margin

17.89

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
17.89
11.51
--
--
--
Peer Median
--
0.00
0.00
0.00
--

Growth

View Detailed Peer Comparison

Revenue Growth

88.77

Higher than Peers by 69.48

Year on year growth in net sales

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
88.77
--
--
--
--
Peer Median
19.29
35.34
69.01
251.95
--
EBIT Growth

203.65

Higher than Peers by 182.24

Year on year growth in operating profit (EBIT)

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
203.65
--
--
--
--
Peer Median
21.41
45.38
4,139.53
1,176.43
--
Net Profit Growth

237.76

Higher than Peers by 90.60

Year on year growth in profit after tax

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
237.76
--
--
--
--
Peer Median
147.16
65.85
686.54
381.29
--
EPS Growth

175.19

Higher than Peers by 28.03

Year on year growth in earnings per share

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
175.19
--
--
--
--
Peer Median
147.16
--
--
305.77
--
Book Value Growth

266.73

--

Year on year growth in book value per share

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
266.73
--
--
--
--
Peer Median
--
--
--
--
--

Solvency

View Detailed Peer Comparison

Debt to Equity

0.97

Higher than Peers by 0.66

Total debt / Net worth

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
0.97
2.44
--
--
--
Peer Median
0.32
0.48
0.12
0.10
--
Short term debt to equity ratio

0.50

--

(Short term borrowings / Net worth)

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
0.50
1.12
--
--
--
Peer Median
--
--
--
--
--
Current Ratio

1.58

Lower than Peers by 0.97

Current Assets / Current Liabilities and Provisions

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
1.58
1.11
--
--
--
Peer Median
2.55
1.90
1.53
3.48
--
Quick Ratio

1.03

Lower than Peers by 11.08

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
1.03
0.51
--
--
--
Peer Median
12.10
1.77
2.22
2.71
--
Interest Coverage

7.45

Higher than Peers by 3.41

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
7.45
4.10
--
--
--
Peer Median
4.04
4.81
6.93
6.84
--

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

38.05

Higher than Peers by 14.05

Debtors outstanding / Net Sales * 100

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
38.05
33.76
--
--
--
Peer Median
24.00
33.89
21.39
15.78
--
Asset Turnover

0.99

Higher than Peers by 0.06

Sales / Average Total Assets

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
0.99
0.69
--
--
--
Peer Median
0.94
1.29
0.86
0.79
--
Receivable days

102.08

--

Average Debtors / Sales * 365

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
102.08
123.23
--
--
--
Peer Median
--
--
--
--
--
Inventory Days

102.74

--

Average Inventory / Sales * 365

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
102.74
188.80
--
--
--
Peer Median
--
--
--
--
--
Payable days

86.43

--

Average Creditors / Cost of goods sold * 365

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
86.43
129.93
--
--
--
Peer Median
--
--
--
--
--
Cash Conversion Cycle

118.39

--

Receivable Days + Inventory Days - Payable Days

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
118.39
182.09
--
--
--
Peer Median
--
--
--
--
--

Valuation

View Detailed Peer Comparison

Price / Earnings

--

--

Current share price divided by earning per share in the last twelve months

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
--
--
--
--
--
Peer Median
20.16
51.65
61.00
61.43
--
Price / Book Value

--

--

Current share price divided by book value per share in the latest financial year

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
--
--
--
--
--
Peer Median
2.28
3.04
6.15
9.86
--
EV/EBITDA

1.75

Lower than Peers by 12.71

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
1.75
4.00
--
--
--
Peer Median
14.45
25.55
11.25
17.58
--
Market Cap

--

--

Current Share price multiplied by latest total number of shares outstanding

Company Name
Mar-25
Mar-24
Mar-23
Mar-22
Mar-21
Avience Biomedicals
--
--
--
--
--
Peer Median
252
126
36
46
--
loading...
loading...
loading...
loading...